Business Context and Reporting Period
This Form 8-K Current Report was filed by Cerecor Inc. on December 21, 2015, reporting events occurring on December 17, 2015, and December 20, 2015. The filing addresses significant changes in executive leadership and board composition. Note: The request metadata referenced "Avalo Therapeutics, Inc.", but the source document explicitly identifies the registrant as Cerecor Inc.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Resignation of CEO and Director: Blake Paterson resigned as President, Chief Executive Officer, and member of the Board of Directors, effective December 31, 2015.
- Appointment of New CEO: Uli Hacksell, Ph.D., was appointed as Chief Executive Officer, effective January 1, 2016. Dr. Hacksell had previously served as Chairman of the Board since May 2015.
- Leadership Transition: Dr. Hacksell will assume the role of principal executive officer upon the effective date of his appointment.
Outlook, Risks, and Management Commentary
The filing includes a Regulation FD disclosure referencing a press release issued on December 21, 2015, which announced the leadership transition. The document highlights Dr. Hacksell's extensive background, including his tenure as CEO of ACADIA Pharmaceuticals Inc. (2000–2015) and senior executive roles at Astra AB. No specific financial guidance, risk factors, or contingencies are detailed in this specific filing.
Investor Verification Checklist
- Verify the exact effective dates for Blake Paterson's departure (Dec 31, 2015) and Uli Hacksell's appointment (Jan 1, 2016).
- Review the accompanying press release (Exhibit 99.1) for additional details on the strategic rationale for the leadership change.
- Confirm the current status of the Board of Directors following Mr. Paterson's resignation.
- Check subsequent filings for any compensation arrangements related to the new CEO appointment.